Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart

Argenx SE announced successful results from a large clinical trial of Vyvgart, an autoimmune treatment. The company's share price increased following the announcement. Vyvgart is approved for treatment of generalized myasthenia gravis.

Next story